Recombinant human erythropoietin (rHuEPO) is an extremely valuable agent now widely used in the treatment of anaemia. This volume offers a complete review of current knowledge on the physiology of EPO and the therapeutic applications of rHuEPO. Leading authorities cover many topical subjects from the regulation of EPO gene expression to the side effects of rHuEPO therapy and experiences with this potent glycoprotein growth factor in predialytic renal failure. The comparative efficacy of subcutaneous versus intravenous and of daily versus thrice weekly rHuEPO administration is also evaluated. Discussion is provided on new indications for the use of rHuEPO in non-renal anaemias, including malignancy, chemotherapy, AIDS and prematurity, based on the latest clinical trials conducted worldwide.